Business Finland is organizing a Trade Mission to Hong Kong on 10-12 September 2025 targeted for Finnish life science companies. This visit is arranged coinciding with BIOHK2025.
This trade mission focuses on three critical areas:
- Investment Engagement: Direct connections with investors from Hong Kong and Mainland China
- Innovation & Incubation: Leveraging new funding schemes for international companies
- Clinical Trials & Data Access: Exploring pathways to access patient data for clinical development
Why Hong Kong?
- Asia's Premier Biotech Hub: Hong Kong is a leading fundraising hub in Asia, supported by the government’s strategic HKD 10 billion investment in life and health technologies.
- New HKD 200 Million Incubation Fund: Recently approved legislation offers significant funding opportunities. We will explore how Finnish companies can benefit through collaboration with the Hong Kong-Shenzhen Innovation and Technology Park (HSITP).
- Gateway to Clinical Data & Trials: Hong Kong's Health Bureau has established a Clinical Research Lab to support trials. We are actively engaging with senior officials on accessing patient data from Mainland China via Hong Kong—a key work-in-progress initiative.
- Synergy with Major Events: Activities are aligned with BIOHK2025 to maximize visibility and engagement with regional stakeholders.
Who Should Attend?
This visit is aimed for Finnish life science companies looking for:
- Investment from Asian capital sources
- Strategic Partnerships for product development & market access
- Access to patient data
Practicalities
Participants are responsible for covering their own travel-related expenses, including flights, accommodation, local transportation, and any meals not included in the official program. Further, attendance at BIOHK2025 is subject to an individual ticket fee payable by each participant.
